

## Immunoglobulin, human normal – Kiovig®

## First-line IVIG for use in CUH is Kiovig®

| Kiovig <sup>®</sup> dosing is w |  |  |           | document   |        | nt before a  | administr | ation |  |
|---------------------------------|--|--|-----------|------------|--------|--------------|-----------|-------|--|
|                                 | CAUTIC   | <b>DN:</b> High  | Administr | ation Risk | Rating |              |           |       |  |
| Form                            | Bottles containing Normal Human Immunoglobulin (IVIg) <b>100mg/mL</b> : 2.5g in 25mL, 5g in 50mL, 10g in 100mL, 20g in 200mL, 30g in 300mL   |  |           |            |        |              |           |       |  |
| Reconstitution                  | Already in solution  |  |           |            |        |              |           |       |  |
| Compatibility &<br>Stability    | Dilution not generally required but KIOVIG may be diluted with glucose 5% solution to a final concentration of 50 mg/mL (5% immunoglobulin).   |  |           |            |        |              |           |       |  |
| Administration<br>Method        | yellow. Do r<br>IV Infusio<br>Initial rate (<br>If the patier  | The solution should be clear or slightly opalescent and colourless or pale yellow. Do not use solutions that are cloudy or have deposits. <b>IV Infusion</b> Initial rate 0.5mL/kg per hour for 30 minutes.           If the patient tolerates the infusion well, the dose may be increased at 30 minute intervals up to a maximum of 6ml/kg/hour. Use an infusion pump. |           |            |        |              |           |       |  |
|                                 | Infusion rat   | Infusion rates based on a range of body weights:           Prescribed         Patient's weight (kg)  |           |            |        |              |           |       |  |
|                                 | rate in<br>mL/kg/hr  | 40   | 50        | 60         | 70     | 80<br>mL/hou | 90<br>r   | 100   |  |
|                                 | 0.5  | 20   | 25        | 30         | 35     | 40           | 45        | 50    |  |
|                                 | 1  | 40   | 50        | 60         | 70     | 80           | 90        | 100   |  |
|                                 | 2  | 80   | 100       | 120        | 140    | 160          | 180       | 200   |  |
|                                 | 4  | 160  | 200       | 240        | 280    | 320          | 360       | 400   |  |
|                                 | 6  | 240  | 300       | 360        | 420    | 480          | 540       | 600   |  |
| Documentation<br>Requirements   | This is a blood product, therefore batch and expiry should be recorded in patient's notes.   |  |           |            |        |              |           |       |  |
| Adverse Drug<br>Reactions       | Infusion related reactions: In case of adverse reaction, either the rate of administration must be reduced or the infusion stopped.  |  |           |            |        |              |           |       |  |
| Monitoring                      | <ul> <li>Monitor BP, heart rate, oxygen saturation, respiratory rate and temperature during initial rate and hourly during infusion.</li> <li>Monitor urine output and serum creatinine levels.</li> </ul>   |  |           |            |        |              |           |       |  |
| Additional<br>Information       | <ul> <li>In all patients, IVIg administration requires:<br/>- adequate hydration prior to the initiation of the infusion of IVIg         - avoidance of concomitant use of loop diuretics</li> <li>Prescriber should round dose down to nearest whole vial size to minimise         waste.</li> <li>Refer to Adult Intravenous Immunoglobulin (IVIG) Prescription         and Administration Record</li> </ul> |  |           |            |        |              |           |       |  |

## Information relates to Kiovig<sup>®</sup> manufactured by Shire.

This information has been summarised to act as a guide for those administering IV medication. The monograph should be used in conjunction with the drug data sheet and BNF for information on dose, adverse effects, cautions and contra-indications. Further information is available from Pharmacy on 22146 or 22542